Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Demerol (Meperidine) Market by Product Type (Powder, Liquid) and by Application (Anesthesia, Cough Treatment, Diarrhea Treatment): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03331

Pages: NA

Charts: NA

Tables: NA

Demerol (meperidine), chemically known as ethyl 1-methyl-4-phenylisonipecotate hydrochloride, is an opioid pain medication. An opioid is sometimes referred to as narcotics. Opioids are drugs that act on the nervous system to relieve pain. The term opioid refers to all substances (exogenous or endogenous) with morphine-like properties. Meperidine is used to treat moderate-to-severe pain.

The growth in the incidence of infectious diseases & chronic pain are anticipated to augment the market growth. A rise in disposable income and surge in global geriatric population are expected to propel the global demerol (meperidine) market. However, emergence and legalization of alternative treatments of opioids such as cannabis impede the growth of the market.

The global demerol (meperidine) market is segmented on the basis of product type, application, and geography. Based on product type, it is bifurcated into powder and liquid. On the basis of application, the market is divided into anaesthesia, cough treatment, and diarrhoea treatment. By geography, it has been analysed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Purdue Pharma, Egalet Corporation, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Sanofi, Sun Pharmaceuticals, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Actavis PLC, and Pfizer, Inc. have been provided in this report.

Key Benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate imminent investment pockets.
  • It offers a quantitative analysis to enable stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions has been provided to determine prevailing opportunities.
  • Key players have been profiled and their strategies thoroughly analyzed to understand the competitive outlook of the global market.
  • Extensive analysis by product elucidates the use of demerol (meperidine) in medical settings

 Key Market Segments

  • By Product Type
    • Powder
    • Liquid
  • By Application
    • Anesthesia
    • Cough Treatment
    • Diarrhea Treatment
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Purdue Pharma
  • Mallinckrodt Pharmaceuticals
  • Pfizer, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Sun Pharmaceuticals
  • Egalet Corporation
  • Sanofi
  • Endo Pharmaceuticals Inc.
  • Actavis PLC
  • Boehringer Ingelheim

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: DEMEROL (MEPERIDINE) MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Powder

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Liquid

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: DEMEROL (MEPERIDINE) MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Anesthesia

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Cough Treatment

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Diarrhea Treatment

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: DEMEROL (MEPERIDINE) MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product Type

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Demerol (meperidine) Market

        • 6.2.5.1. Market Size and Forecast, By Product Type
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Demerol (meperidine) Market

        • 6.2.6.1. Market Size and Forecast, By Product Type
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Demerol (meperidine) Market

        • 6.2.7.1. Market Size and Forecast, By Product Type
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product Type

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Demerol (meperidine) Market

        • 6.3.5.1. Market Size and Forecast, By Product Type
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Demerol (meperidine) Market

        • 6.3.6.1. Market Size and Forecast, By Product Type
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Demerol (meperidine) Market

        • 6.3.7.1. Market Size and Forecast, By Product Type
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Demerol (meperidine) Market

        • 6.3.8.1. Market Size and Forecast, By Product Type
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Demerol (meperidine) Market

        • 6.3.9.1. Market Size and Forecast, By Product Type
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Demerol (meperidine) Market

        • 6.3.10.1. Market Size and Forecast, By Product Type
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Demerol (meperidine) Market

        • 6.3.11.1. Market Size and Forecast, By Product Type
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product Type

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Demerol (meperidine) Market

        • 6.4.5.1. Market Size and Forecast, By Product Type
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Demerol (meperidine) Market

        • 6.4.6.1. Market Size and Forecast, By Product Type
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Demerol (meperidine) Market

        • 6.4.7.1. Market Size and Forecast, By Product Type
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Demerol (meperidine) Market

        • 6.4.8.1. Market Size and Forecast, By Product Type
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Demerol (meperidine) Market

        • 6.4.9.1. Market Size and Forecast, By Product Type
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Demerol (meperidine) Market

        • 6.4.10.1. Market Size and Forecast, By Product Type
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Demerol (meperidine) Market

        • 6.4.11.1. Market Size and Forecast, By Product Type
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Demerol (meperidine) Market

        • 6.4.12.1. Market Size and Forecast, By Product Type
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Demerol (meperidine) Market

        • 6.4.13.1. Market Size and Forecast, By Product Type
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product Type

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Demerol (meperidine) Market

        • 6.5.5.1. Market Size and Forecast, By Product Type
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Demerol (meperidine) Market

        • 6.5.6.1. Market Size and Forecast, By Product Type
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Demerol (meperidine) Market

        • 6.5.7.1. Market Size and Forecast, By Product Type
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Demerol (meperidine) Market

        • 6.5.8.1. Market Size and Forecast, By Product Type
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Demerol (meperidine) Market

        • 6.5.9.1. Market Size and Forecast, By Product Type
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Demerol (meperidine) Market

        • 6.5.10.1. Market Size and Forecast, By Product Type
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Purdue Pharma

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Egalet Corporation

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Boehringer Ingelheim

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Janssen Pharmaceuticals, Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Sanofi

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Sun Pharmaceuticals

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Mallinckrodt Pharmaceuticals

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Endo Pharmaceuticals Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Actavis PLC

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Pfizer, Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DEMEROL (MEPERIDINE) MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL DEMEROL (MEPERIDINE) MARKET FOR POWDER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL DEMEROL (MEPERIDINE) MARKET FOR LIQUID, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL DEMEROL (MEPERIDINE) MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL DEMEROL (MEPERIDINE) MARKET FOR ANESTHESIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL DEMEROL (MEPERIDINE) MARKET FOR COUGH TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL DEMEROL (MEPERIDINE) MARKET FOR DIARRHEA TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL DEMEROL (MEPERIDINE) MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. NORTH AMERICA DEMEROL (MEPERIDINE), BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 12. U.S. DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 13. U.S. DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 14. CANADA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 15. CANADA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 16. MEXICO DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 18. EUROPE DEMEROL (MEPERIDINE), BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 21. FRANCE DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 23. GERMANY DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. ITALY DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 26. ITALY DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 27. SPAIN DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 29. UK DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 30. UK DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 31. RUSSIA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 33. REST OF EUROPE DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. ASIA-PACIFIC DEMEROL (MEPERIDINE), BY REGION, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. CHINA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 39. CHINA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 40. JAPAN DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 42. INDIA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 43. INDIA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. SOUTH KOREA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 46. AUSTRALIA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 48. THAILAND DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. MALAYSIA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 52. INDONESIA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 56. LAMEA DEMEROL (MEPERIDINE), BY REGION, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 59. BRAZIL DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 61. SOUTH AFRICA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. SAUDI ARABIA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 65. UAE DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 66. UAE DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 67. ARGENTINA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. REST OF LAMEA DEMEROL (MEPERIDINE), BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA DEMEROL (MEPERIDINE), BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 71. PURDUE PHARMA: KEY EXECUTIVES
  • TABLE 72. PURDUE PHARMA: COMPANY SNAPSHOT
  • TABLE 73. PURDUE PHARMA: OPERATING SEGMENTS
  • TABLE 74. PURDUE PHARMA: PRODUCT PORTFOLIO
  • TABLE 75. PURDUE PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. EGALET CORPORATION: KEY EXECUTIVES
  • TABLE 77. EGALET CORPORATION: COMPANY SNAPSHOT
  • TABLE 78. EGALET CORPORATION: OPERATING SEGMENTS
  • TABLE 79. EGALET CORPORATION: PRODUCT PORTFOLIO
  • TABLE 80. EGALET CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 82. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 83. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 84. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 85. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. JANSSEN PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 87. JANSSEN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 88. JANSSEN PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 89. JANSSEN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 90. JANSSEN PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. SANOFI: KEY EXECUTIVES
  • TABLE 92. SANOFI: COMPANY SNAPSHOT
  • TABLE 93. SANOFI: OPERATING SEGMENTS
  • TABLE 94. SANOFI: PRODUCT PORTFOLIO
  • TABLE 95. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. SUN PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 97. SUN PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 98. SUN PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 99. SUN PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 100. SUN PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. MALLINCKRODT PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 102. MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 103. MALLINCKRODT PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 104. MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 105. MALLINCKRODT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. ENDO PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 107. ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 108. ENDO PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 109. ENDO PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 110. ENDO PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. ACTAVIS PLC: KEY EXECUTIVES
  • TABLE 112. ACTAVIS PLC: COMPANY SNAPSHOT
  • TABLE 113. ACTAVIS PLC: OPERATING SEGMENTS
  • TABLE 114. ACTAVIS PLC: PRODUCT PORTFOLIO
  • TABLE 115. ACTAVIS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 117. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 118. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 119. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 120. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DEMEROL (MEPERIDINE) MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DEMEROL (MEPERIDINE) MARKET
  • FIGURE 3. SEGMENTATION DEMEROL (MEPERIDINE) MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DEMEROL (MEPERIDINE) MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDEMEROL (MEPERIDINE) MARKET
  • FIGURE 11. DEMEROL (MEPERIDINE) MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. DEMEROL (MEPERIDINE) MARKET FOR POWDER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. DEMEROL (MEPERIDINE) MARKET FOR LIQUID, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. DEMEROL (MEPERIDINE) MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. DEMEROL (MEPERIDINE) MARKET FOR ANESTHESIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. DEMEROL (MEPERIDINE) MARKET FOR COUGH TREATMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. DEMEROL (MEPERIDINE) MARKET FOR DIARRHEA TREATMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: DEMEROL (MEPERIDINE) MARKET
  • FIGURE 24. TOP PLAYER POSITIONING, 2024
  • FIGURE 25. PURDUE PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 26. PURDUE PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 27. PURDUE PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 28. EGALET CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. EGALET CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. EGALET CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. BOEHRINGER INGELHEIM: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. JANSSEN PHARMACEUTICALS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. JANSSEN PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. JANSSEN PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. SUN PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. SUN PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. SUN PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. MALLINCKRODT PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. ENDO PHARMACEUTICALS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. ENDO PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. ENDO PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. ACTAVIS PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. ACTAVIS PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. ACTAVIS PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. PFIZER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. PFIZER, INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Demerol (Meperidine) Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved